Skip to main content
. Author manuscript; available in PMC: 2026 Jan 6.
Published in final edited form as: Cell Rep. 2025 Nov 10;44(11):116516. doi: 10.1016/j.celrep.2025.116516

Figure 7. miR-181d-mediated cell-to-cell variation of MGMT increased TMZ resistance.

Figure 7.

(A) TMZ reduced miR-181d expression and increased the variation in MGMT expression. BT-83 cells were treated with TMZ or DMSO. Single-cell RT-qPCR was performed on approximately 80 cells per treatment group to assess miR-181d and MGMT, with the data presented as a distribution. Black: DMSO and Red: TMZ treatment.

(B) miR-181d transfection suppressed TMZ-induced variability in MGMT expression. The cells were transfected with miR-181d before TMZ treatment and single-cell RT-qPCR.

(C) Kaplan-Meier survival curves of nude mice bearing intracranial BT-83 cells with low-variance (LV) and high-variance (HV) in MGMT expression. The mice underwent the intraperitoneal administration of TMZ at 50 mg/kg/day for 5 days, followed by a 23-day treatment interruption. TMZ treatment was initiated 7 days post-tumor implantation. Each group consisted of 10 mice.

(D and E) The low- and high-variance cells were transfected with miR-181d and implanted into nude mice. The mice were treated with TMZ as described (C). The study was continued for 90 days. Low- (D) and high-variance (E). Data are represented as mean ± SD.